Some proponents of CETA make the argument that drug prices are lower in Europe even though they have longer, stronger intellectual property provisions. They point to that as an argument that if we strengthen our intellectual property provisions in pharmaceutical drugs in Canada, therefore there is no relationship to that in cost. What's your comment on that?
On February 13th, 2014. See this statement in context.